AzTrials
AzTrials

Disc DegenerationNCT03442374

Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle Recovery

A study testing Exercise in people with Disc Degeneration and Low Back Pain, run by University of California, San Diego at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Low back pain (LBP) is a complex condition that affects 65-85% of the population, and is the leading musculoskeletal condition contributing to disability in the United States. Disc herniation is the most common injury and 75% of individuals undergoing surgical and rehabilitative interventions for this condition… Read more about this study

Who is it for?
Ages 21 to 85 years
Conditions the study is for
Disc Degeneration, Low Back Pain
What is being tested?
Exercise
Could I receive a placebo?
No, everyone receives an active treatment
How many people
62 participants
Where
1 siteUnited States
Study dates
1 Jul 2019to 1 Oct 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Spine pathologies requiring un-instrumented surgery (i.e. laminectomy, laminoforaminotomy, or discectomy).
  • Age 21-85 years of age.

Who cannot join

  • History of lumbar spine surgery.
  • Patients requiring placement of instrumentation as part of the surgical procedure (i.e. fusion).
  • Diabetes.
  • Neuromuscular diseases.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UC San Diego

    La Jolla, California, 92093

Other trials in United States

About this study

Official title: Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle

Low back pain (LBP) is a complex condition that affects 65-85% of the population, and is the leading musculoskeletal condition contributing to disability in the United States. Disc herniation is the most common injury and 75% of individuals undergoing surgical and rehabilitative interventions for this condition experience suboptimal or poor outcomes. These patients demonstrate disability and deficits in functional capacity, including strength and endurance of the lumbar musculature. Muscle-specific changes in individuals with LBP include altered muscle volume, fatty infiltration and fibrosis, and fiber area and type. Importantly, these changes are insensitive to rehabilitation in patients with continued chronic or recurrent symptoms. While normal disuse-related atrophy in the presence of LBP is expected, more severe or chronic pathology, such as inflammation and fiber damage, may be inducing irreversible fiber degeneration and fatty/fibrotic tissue changes that impair muscle function and recovery. While the structural and adaptive capacities of healthy muscle are well understood, muscle recovery in the presence of pathology is less clear. To address this gap in knowledge, the purpose of this project is to compare structural, physiological, and adaptive responses of muscle in the presence of acute and chronic lumbar spine pathology. The central hypothesis is that chronic injury results in a state of muscle inflammation, atrophy, fibrosis, and muscle degeneration that is not responsive to exercise. The Investigators will identify which patients respond to exercise by examining muscle hypertrophic, fibrotic, inflammatory, and adipogenic gene expression profiles. Patients will be followed for six months post-operatively to measure muscle recovery and strength.

Read the detailed description

AIM: To determine the effect of exercise on induction of muscle hypertrophic, fibrotic, inflammatory, and adipogenic pathways in patients with mild versus severe fatty infiltration of the multifidus muscle. Rationale. The objectives of this aim are to 1) measure molecular responses of muscle to a well-defined bout of pre-operative exercise, and 2) to determine if baseline morphological or exercise-induced molecular responses predict muscle structural recovery and functional gains up to 6 months post-operatively.

Design. This will be a longitudinal study of 40 patients with mild (< 20%) versus severe (> 50%) fatty infiltration. Non-exercise controls will also be important and the investigators intend to use a portion of biopsied tissue from other experiments as additional controls. Prior to surgery, patients will undergo clinical and MRI examinations. Additionally, patients will undergo an exercise bout 6 hours pre-operatively, and then immediately undergo a short MRI imaging protocol to measure exercise-induced perfusion changes (IVIM). Six hours after the exercise bout, the investigators will collect biopsies of the multifidus during surgery to characterize the hypertrophic, fibrotic, adipogenic, and inflammatory responses. For primary analyses, patient groups will be selected on the basis of severity of muscle fatty infiltration. Group ages and genders will be matched because the investigators know that baseline and exercise-induced gene expression varies with age. Surgical procedure and manipulation of the disc intraoperatively will be documented to account for the potential for disc and other surgery-specific effects on muscle structure. Six months post-operatively, repeated measures of muscle structure will be made via MRI. At 6, 12, and 24 weeks, strength (isokinetic dynamometer) and patient-specific function (questionnaire data) will be obtained as per standard protocol.

Methods:

Physical Examination: A physical therapist with spine injury experience will conduct the clinical exam. Age, gender and body mass index (BMI), duration of symptoms, anti-inflammatory drug use, active and passive range of motion, provocative neural tension tests (measuring joint range of motion [ROM]), strength and endurance as measured on an isokinetic dynamometer (MedX Holdings Inc.), neurovascular status, Oswestry Disability Index (81), Baecke Physical Activity Questionnaire (BPA), Fear Avoidance Beliefs Questionnaire (FABQ), and Pain Catastrophizing Scale (PCS) are important measures that capture both physical and psychosocial factors known to be related to LBP and will be collected at the clinical site. This screen will be used to confirm that discogenic symptoms are isolated to levels below L4, which allows us to use vastus lateralis as an internal control muscle biopsy.

Clinical MRI: Standard axial, sagittal oblique, and coronal oblique MR images of the spine will be collected on all patients who are scheduled for surgery. To identify disc injury severity (Pfirrmann grade), muscle fatty infiltration (Kjaer grade), and to confirm injury location, T1 and T2 non-fat suppressed or contrast-enhanced axial and sagittal MR images of the spine joint will be used.

Multimodal MRI: Imaging will be performed in a single session on a state-of-the-art 3T MRI system (GE MR750). The quantity and distribution of spine muscle volume, fat volume, and connective tissue volume will be performed from supine scans using high-resolution (1mm3) 3D FSPGR, IDEAL fat-water separation, and UTE pulse sequences, respectively using a 32-channel spine array coil. IVIM will be used to quantify regional muscle activation in response to an exercise bout.

Exercise protocol: Prior to surgery, patients will be subjected to a lumbar spine exercise protocol on a MedX Lumbar extension dynamometer with a pelvic restraint system allowing for isolation of lumbar spine muscles. The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension.

Diet protocol: Importantly, the patients will remain NPO (no food or water) after the exercise bout but will have a standardized diet for 24 hours prior to the exercise bout and surgery, which mitigates the effects of diet on gene expression (137, 150-152). Evening meals will be standardized (1900h: 11 kcal/kg; 60% carbohydrate [CHO], 25% fat [FAT], 15% protein [PRO]; 2200h (3 kcal/kg; 95% CHO, 2% FAT, 3% PRO) because meal composition can acutely impact gene and protein expression.

Harvesting and storage of muscle biopsy: Muscle biopsies will be harvested within 6 hours of the exercise bout at their scheduled surgery time. Subjects will be excluded from the analysis if their biopsies are not harvested within 1 hour of the prescribed time point. Biopsies will be obtained with a standard biopsy clamp at the middle and deep margins of the multifidus muscle as noted in Aim #1 and immediately placed in RNAlater (Qiagen) for subsequent qPCR analysis or frozen in liquid nitrogen for protein abundance/phosphorylation measurements.

qPCR and western blotting: Gene expression and protein abundance will be measured by, qPCR and western blotting, respectively. Briefly, real-time PCR will be performed in a Bio-Rad CFX384 using customized plates (PrimePCR, Bio-Rad). Target gene expression will be calculated relative to values from 18S ribosomal subunit, as preliminary findings demonstrate it to be more stable than glyceraldehyde-3-phosphate dehydrogenase (GAPDH; data not presented). For genes in which we find a greater than 3-fold change in expression, western blotting will be used to assess protein abundance, as previously described.

Being tested
Exercise
Keywords
Multifidus, Muscle, Degeneration, Lumbar Spine, Disc
Medical subject headings
Intervertebral Disc Degeneration, Low Back Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ExerciseOther

    The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension

Study groups in NCT03442374
Study groupRoleWhat they receive
ExerciseExperimentalA single bout of moderate intensity lumbar extensor muscle exercise.
Receives: Other: Exercise
Non-exerciseNo interventionNo exercise intervention.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Multifidus Muscle Fatty Infiltration

    (% fat at 6 months - % fat at baseline / % fat at baseline)

    Measured: 6 months

Secondary outcomes (59)
  1. Change in Oswestry Disability Index (ODI)

    Disability Questionnaire (10 questions, % scale is sum of 10 questions/50, higher score is worse), 6 months - baseline

    Measured: 6 Months

  2. Change in Fear Avoidance Beliefs Questionnaire (FABQ)

    Fear Avoidance Behaviors (sumo 16 items, 0-64 scale, higher score is worse), 6 months- baseline

    Measured: 6 months

  3. Change in Pain Catastrophizing Scale (PCS)

    Pain behaviors questionnaire (sum of 13 items, 0-52 scale, higher score is worse), 6 months - baseline

    Measured: 6 months

  4. Change in Activated Muscle Volume (%)

    (% muscle activation after exercise - % muscle activation at baseline / % muscle activation at baseline)

    Measured: After exercise (within 5 minutes)

  5. Change in Pain (VAS)

    Visual Analog Scale (0-100 mm scale), 6 months - baseline

    Measured: 6 months

  6. Change in Strength

    MedEx dynamometer, Back Extensor Strength (Nm), 6 months - baseline

    Measured: 6 months

  7. MYHC3 gene expression (delta CT/delta CT)

    Embryonic myosin heavy chain gene expression

    Measured: 6 hours after a single exercise bout

  8. MHY3 protein abundance (ug/mg)

    Embryonic myosin heavy chain protein abundance

    Measured: 6 hours after a single exercise bout

  9. MYOG gene expression (delta CT/delta CT)

    Myogenin gene expression

    Measured: 6 hours after a single exercise bout

  10. MYOG protein abundance (ug/mg)

    Myogenin protein abundance

    Measured: 6 hours after a single exercise bout

  11. PAX7 gene expression (delta CT/delta CT)

    PAX7 gene expression

    Measured: 6 hours after a single exercise bout

  12. PAX7 gene expression (ug/mg)

    PAX7 protein abundance

    Measured: 6 hours after a single exercise bout

  13. ANKRD2 gene expression (delta CT/delta CT)

    ANKRD2 gene expression

    Measured: 6 hours after a single exercise bout

  14. ANKRD2 protein abundance (ug/mg)

    ANKRD2 protein abundance

    Measured: 6 hours after a single exercise bout

  15. MTOR gene expression (delta CT/delta CT)

    MTOR gene expression

    Measured: 6 hours after a single exercise bout

  16. MTOR protein abundance (ug/mg)

    MTOR protein abundance

    Measured: 6 hours after a single exercise bout

  17. COL1A1 gene expression (delta CT/delta CT)

    COL1A1 gene expression

    Measured: 6 hours after a single exercise bout

  18. COL3A1 gene expression (delta CT/delta CT)

    COL3A1 gene expression

    Measured: 6 hours after a single exercise bout

  19. COL9A1 gene expression (delta CT/delta CT)

    COL9A1 gene expression

    Measured: 6 hours after a single exercise bout

  20. LOX gene expression (delta CT/delta CT)

    LOX gene expression

    Measured: 6 hours after a single exercise bout

  21. CTGF gene expression (delta CT/delta CT)

    CTGF gene expression

    Measured: 6 hours after a single exercise bout

  22. TGFB1 gene expression (delta CT/delta CT)

    TGFB1 gene expression

    Measured: 6 hours after a single exercise bout

  23. MMP1 gene expression (delta CT/delta CT)

    MMP1 gene expression

    Measured: 6 hours after a single exercise bout

  24. MMP3 gene expression (delta CT/delta CT)

    MMP3 gene expression

    Measured: 6 hours after a single exercise bout

  25. MMP9 gene expression (delta CT/delta CT)

    MMP9 gene expression

    Measured: 6 hours after a single exercise bout

  26. CEBPA gene expression (delta CT/delta CT)

    CEBPA gene expression

    Measured: 6 hours after a single exercise bout

  27. FABP4 gene expression (delta CT/delta CT)

    FABP4 gene expression

    Measured: 6 hours after a single exercise bout

  28. PPARG gene expression (delta CT/delta CT)

    PPARG gene expression

    Measured: 6 hours after a single exercise bout

  29. PPARD gene expression (delta CT/delta CT)

    PPARD gene expression

    Measured: 6 hours after a single exercise bout

  30. LEP gene expression (delta CT/delta CT)

    LEP gene expression

    Measured: 6 hours after a single exercise bout

  31. ADIPOQ gene expression (delta CT/delta CT)

    ADIPOQ gene expression

    Measured: 6 hours after a single exercise bout

  32. CASP1 gene expression (delta CT/delta CT)

    CASP1 gene expression

    Measured: 6 hours after a single exercise bout

  33. CASP3 gene expression (delta CT/delta CT)

    CASP3 gene expression

    Measured: 6 hours after a single exercise bout

  34. TNFa gene expression (delta CT/delta CT)

    TNFa gene expression

    Measured: 6 hours after a single exercise bout

  35. IL10 gene expression (delta CT/delta CT)

    IL10 gene expression

    Measured: 6 hours after a single exercise bout

  36. IL6 gene expression (delta CT/delta CT)

    IL6 gene expression

    Measured: 6 hours after a single exercise bout

  37. IL1B gene expression (delta CT/delta CT)

    IL1B gene expression

    Measured: 6 hours after a single exercise bout

  38. COL1A1 Protein abundance (ug/mg)

    COL1A1 Protein abundance

    Measured: 6 hours after a single exercise bout

  39. COL3A1 Protein abundance (ug/mg)

    COL3A1 Protein abundance

    Measured: 6 hours after a single exercise bout

  40. COL9A1 Protein abundance (ug/mg)

    COL9A1 Protein abundance

    Measured: 6 hours after a single exercise bout

  41. LOX Protein abundance (ug/mg)

    LOX Protein abundance

    Measured: 6 hours after a single exercise bout

  42. CTGF Protein abundance (ug/mg)

    CTGF Protein abundance

    Measured: 6 hours after a single exercise bout

  43. TGFB1 Protein abundance (ug/mg)

    TGFB1 Protein abundance

    Measured: 6 hours after a single exercise bout

  44. MMP1 Protein abundance (ug/mg)

    MMP1 Protein abundance

    Measured: 6 hours after a single exercise bout

  45. MMP3 Protein abundance (ug/mg)

    MMP3 Protein abundance

    Measured: 6 hours after a single exercise bout

  46. MMP9 Protein abundance (ug/mg)

    MMP9 Protein abundance

    Measured: 6 hours after a single exercise bout

  47. CEBPA Protein abundance (ug/mg)

    CEBPA Protein abundance

    Measured: 6 hours after a single exercise bout

  48. FABP4 Protein abundance (ug/mg)

    FABP4 Protein abundance

    Measured: 6 hours after a single exercise bout

  49. PPARG Protein abundance (ug/mg)

    PPARG Protein abundance

    Measured: 6 hours after a single exercise bout

  50. PPARD Protein abundance (ug/mg)

    PPARD Protein abundance

    Measured: 6 hours after a single exercise bout

  51. LEP Protein abundance (ug/mg)

    LEP Protein abundance

    Measured: 6 hours after a single exercise bout

  52. ADIPOQ Protein abundance (ug/mg)

    ADIPOQ Protein abundance

    Measured: 6 hours after a single exercise bout

  53. CASP1 Protein abundance (ug/mg)

    CASP1 Protein abundance

    Measured: 6 hours after a single exercise bout

  54. CASP3 Protein abundance (ug/mg)

    CASP3 Protein abundance

    Measured: 6 hours after a single exercise bout

  55. TNFa Protein abundance (ug/mg)

    TNFa Protein abundance

    Measured: 6 hours after a single exercise bout

  56. IL10 Protein abundance (ug/mg)

    IL10 Protein abundance

    Measured: 6 hours after a single exercise bout

  57. IL6 Protein abundance (ug/mg)

    IL6 Protein abundance

    Measured: 6 hours after a single exercise bout

  58. IL1B Protein abundance (ug/mg)

    IL1B Protein abundance

    Measured: 6 hours after a single exercise bout

  59. Change in Multifidus muscle volume (%)

    Multifidus muscle volume (cc), (6 months - baseline/baseline)

    Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Feb 2018
  2. Study start1 Jul 2019
  3. Primary completion1 Jun 2023
  4. Study completion1 Oct 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Stratified by fatty infiltration severity (n=20/group x 2 groups + non exercise controls n=20)
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
62 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03442374
Sponsor's protocol ID
HD088437
Status last verified
Nov 2023
First submitted
9 Feb 2018
Last updated
28 Nov 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Exercise in people with Disc Degeneration and Low Back Pain, run by University of California, San Diego at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Multifidus Muscle Fatty Infiltration (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in